Vaximm reports final Phase I data for VXM01 in recurrent glioblastoma

Vaximm AG (Basel, Switzerland) reported final data from 14 patients with recurrent glioblastoma in a Phase I trial showing that oral VXM01 on days 1, 3, 5 and 7 led to one durable objective response in a patient that also received treatment with PD-1 inhibitor Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY). Seven patients were still alive during a 20-month observation period. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

The open-label, German trial enrolled patients with recurrent glioblastoma who progressed following radiochemotherapy that included temozolomide. Three of the 14 patients also received a PD-1 inhibitor. During the follow-up period, patients could receive single doses of VXM01 every four weeks (see BioCentury Innovations, Oct. 19, 2017)...